ImmunityBio
IBRX
IBRX
62 hedge funds and large institutions have $43.5M invested in ImmunityBio in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 22 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
22% less capital invested
Capital invested by funds: $56.1M → $43.5M (-$12.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
62
Holding in Top 10
–
Calls
$117K
Puts
$14K
Top Buyers
| 1 | +$489K | |
| 2 | +$392K | |
| 3 | +$345K | |
| 4 |
Renaissance Technologies
New York
|
+$270K |
| 5 |
VF
Virtu Financial
New York
|
+$180K |
Top Sellers
| 1 | -$4.04M | |
| 2 | -$1.01M | |
| 3 | -$982K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$694K |
| 5 |
BlackRock
New York
|
-$491K |